SIO If you attended the SIO Annual Meeting just a couple of weeks ago, be sure to complete the conference evaluation by Friday, 21 February. The evaluation will help provide feedback to help us understand what went well and what can be improved on in the future. To complete the event evaluation:
Download or open the event app on your phone or tablet by searching "SIO Meetings"
Click the CME Credits button on the home page
Complete the Overall Conference Evaluation under "Tasks"
SIO Complete the same steps required to complete the conference evaluation. Complete individual session evaluations for any sessions you attended. Complete the attestation form. All feedback must be submitted before 21 February 2020.
SIO The Society of Interventional Oncology thanks all of our members for an incredible 2019 and looks forward to the exciting developments 2020 will bring. Joining SIO secures your place among the most influential minds in this emerging field and demonstrate your commitment to advancing interventional oncology as well as to enjoy SIO Member Benefits!
Be sure to renew your membership to take advantage of discounts on SIO events, opportunities for exclusive research grants, free CME, and other year round benefits. Instructions for how to renew can be found here.
Scientific Reports The prognostic factors of patients who undergo radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC) is not fully elucidated. Researchers aimed to investigate the role of liver stiffness (LS) and spleen stiffness (SS) measured by acoustic radiation force impulse (ARFI) elastography in determining the prognoses of patients with HCC after RFA. They prospectively enrolled 173 patients with HCC who underwent ARFI elastography for measurement of LS and SS on the same day of RFA. READ MORE
International Journal of Hyperthermia This study aimed to evaluate the safety and efficacy of ultrasound-guided RFA for the treatment of papillary thyroid microcarcinoma (PTMC). The data of 204 nodules from 198 PTMC patients who were treated using RFA were retrospectively reviewed in this study. Demographic variables, complication details and CEUS results in different time points were collected. The volumes and volume reduction rate (VRR) of the ablated area under CEUS at different follow-up time points were calculated and compared.READ MORE
Journal of the American College of Surgeons Liver-directed hepatic arterial therapies are associated with improved survival and effective symptom control for patients with unresectable neuroendocrine liver metastases (NELM). Whether transarterial chemoembolization (TACE) or transarterial radioembolization (TARE) with yttrium-90 (y-90) are associated with improved short- or long-term outcomes is unknown.READ MORE
Pain Medicine Myth: During radiofrequency ablation procedures, inadvertent skin burns occur only due to improper positioning of the electrical dispersion pad. They are not caused by radiofrequency electrodes, as the lesions produced by electrodes cannot reach the overlying skin. Fact: Full-thickness skin burns caused by radiofrequency electrodes have been described as complications of radiofrequency ablation of the thoracic medial branch nerve, the sacral lateral branch nerve and the inferomedial genicular nerve.READ MORE
Cryotherapy is a minimally invasive treatment primarily for kidney, lung, and prostate cancers as well as a palliative treatment for bone pain. It has been used since the 19th Century(see history below), but advancements continue to be made every year.Read more
Specialty Practice Management is a complete front- and back-office solution that offers a rapid return on your investment and improved satisfaction among your staff. Practices with 10 or fewer providers turn to this comprehensive solution to manage self-pay accounts and eliminate the common mistakes that prevent or delay insurance reimbursement.
International Journal of Hyperthermia This study aimed to prospectively compare the effectiveness and safety of percutaneous microwave ablation (PMWA) and ultrasound-guided radiofrequency ablation (USgRFA) for treating symptomatic uterine adenomyosis. 133 women with symptomatic uterine adenomyosis who met the inclusion criteria were enrolled in our study from October 2015 to October 2017. 68 patients underwent PMWA, and 65 patients underwent USgRFA.READ MORE